- Home
- FGBI vs ABOS Comparison
FGBI vs ABOS Comparison
Compare FGBI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGBI | ABOS |
|---|---|---|
| Founded | 1934 | 1996 |
| Country | United States | United States |
| Employees | 346 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 165.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FGBI | ABOS |
|---|---|---|
| Price | $10.81 | $2.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 22.5K | ★ 353.3K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $1.10 |
| 52 Week High | $11.02 | $3.60 |
Technical Indicators
Market Signals| Indicator | FGBI | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 43.62 |
| Support Level | $7.98 | $2.14 |
| Resistance Level | N/A | $2.42 |
| Average True Range (ATR) | 0.42 | 0.14 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 75.66 | 26.64 |
Price Performance
Historical ComparisonAbout FGBI First Guaranty Bancshares Inc.
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.